A10AE06 - Insulin Degludec |
Not porphyrinogenic |
NP |
Mono.Rationale
Insulin degludec has no porphyrinogenic effects.
Mono.ChemicalDescription
Antidiabetic pancreatic hormone consisting of polypeptide chains, connected by disulfide bridges.
Mono.MetabolismAndPharmacokinetics
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, which are slowly and continuously absorbed into the bloodstream leading to a flat and stable glucose-lowering-effect.
Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
Mono.SimilarDrugs
Mono.References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M. Endocrinol Nutr. 2014 Mar;61(3):153-9.
|
23890782 |
| Summary of Product Characteristics | ||
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tresiba.
|
|
Mono.Tradenames
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba FlexTouch · Tresiba Penfill 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Tresiba 
Ins tresiba · Insulin degludec component of ryzodeg · Insulin degludec component of xultophy · Tresiba 
Insuline degludec 
Insulina degludec 
Insulin degludec